Lexeo Retained Earnings from 2010 to 2024

LXEO Stock   7.83  0.50  6.82%   
Lexeo Therapeutics, Retained Earnings yearly trend continues to be very stable with very little volatility. Retained Earnings are likely to grow to about -172.7 M this year. Retained Earnings is the cumulative amount of net income that Lexeo Therapeutics, Common retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals
 
Retained Earnings  
First Reported
2010-12-31
Previous Quarter
-181.8 M
Current Value
-172.7 M
Quarterly Volatility
63.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lexeo Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexeo Therapeutics,'s main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 2.8 M or Depreciation And Amortization of 1.9 M, as well as many indicators such as Price To Sales Ratio of 369, Dividend Yield of 0.0 or PTB Ratio of 3.31. Lexeo financial statements analysis is a perfect complement when working with Lexeo Therapeutics, Valuation or Volatility modules.
  
Check out the analysis of Lexeo Therapeutics, Correlation against competitors.

Latest Lexeo Therapeutics,'s Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Lexeo Therapeutics, Common over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Lexeo Therapeutics,'s Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lexeo Therapeutics,'s overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (181.84 M)10 Years Trend
Slightly volatile
   Retained Earnings   
       Timeline  

Lexeo Retained Earnings Regression Statistics

Arithmetic Mean(39,148,605)
Coefficient Of Variation(162.62)
Mean Deviation49,281,144
Median(5,547,825)
Standard Deviation63,661,917
Sample Variance4052.8T
Range176.3M
R-Value(0.75)
Mean Square Error1924.7T
R-Squared0.56
Significance0
Slope(10,643,321)
Total Sum of Squares56739.8T

Lexeo Retained Earnings History

2024-172.7 M
2023-181.8 M
2022-115.4 M
2021-56.2 M

About Lexeo Therapeutics, Financial Statements

Lexeo Therapeutics, investors utilize fundamental indicators, such as Retained Earnings, to predict how Lexeo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Retained Earnings-181.8 M-172.7 M

Pair Trading with Lexeo Therapeutics,

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lexeo Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lexeo Therapeutics, will appreciate offsetting losses from the drop in the long position's value.

Moving together with Lexeo Stock

  0.69FDMT 4D Molecular TherapeuticsPairCorr
  0.85JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.79MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr

Moving against Lexeo Stock

  0.81BMY Bristol Myers Squibb Aggressive PushPairCorr
  0.66NAMS NewAmsterdam PharmaPairCorr
  0.36MNOV MediciNovaPairCorr
  0.34PHVS Pharvaris BVPairCorr
The ability to find closely correlated positions to Lexeo Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lexeo Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lexeo Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lexeo Therapeutics, Common to buy it.
The correlation of Lexeo Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lexeo Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lexeo Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lexeo Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Lexeo Therapeutics, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lexeo Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lexeo Therapeutics, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lexeo Therapeutics, Common Stock:
Check out the analysis of Lexeo Therapeutics, Correlation against competitors.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexeo Therapeutics,. If investors know Lexeo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexeo Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(12.53)
Return On Assets
(0.40)
Return On Equity
(0.75)
The market value of Lexeo Therapeutics, is measured differently than its book value, which is the value of Lexeo that is recorded on the company's balance sheet. Investors also form their own opinion of Lexeo Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Lexeo Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexeo Therapeutics,'s market value can be influenced by many factors that don't directly affect Lexeo Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexeo Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexeo Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexeo Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.